New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
07:16 EDTAGNAllergan price target raised to $107 from $83 at Piper Jaffray
Piper Jaffray raised its price target for Allergan (AGN) shares to $107 citing the issuance of patents on Restasis. Piper believes the recent valuation expansion of shares is justified but thinks additional expansion is unlikely given the paragraph IV litigation versus Actavis (ACT). The firm reiterates a Neutral rating on Allergan.
News For AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
17:22 EDTAGNAllergan reports 6.7% stake in KYTHERA
June 25, 2015
08:13 EDTAGNAllergan CEO: Irvine campus ‘crucial’ to company, L.A. Times reports
New Allergan CEO Brent Saunders said that the company’s Irvine, California campus is “crucial” to the recently purchased organization, the L.A. Times reports, citing comments from Saunders in an interview. Allergan was purchased in March by Actavis, a move which led to the layoff of roughly 600 employees from the Irvine offices, the report says. Saunders said that the “bleeding has stopped” after a round of layoffs, the L.A. Times says. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use